Financial incentives and counseling aim to help homeless veterans quit smoking

NCT ID NCT07714200

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests a program called Abstinence Reinforcement Therapy (ART+) to help veterans who are homeless quit smoking. The program combines telehealth counseling, nicotine replacement therapy, and financial rewards for staying smoke-free. Researchers will compare ART+ to standard smoking cessation care in 120 veterans, using saliva tests to verify abstinence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of cognitive behavioral therapy, nicotine replacement therapy, bupropion, and mobile contingency management (financial incentives for abstinence)
What this could lead to
If successful, this approach could provide an effective, scalable way to help homeless veterans quit smoking, reducing smoking-related deaths in this high-risk group.
What could go wrong
The trial is relatively small (120 participants) and relies on self-report plus biochemical verification, which may not capture long-term success. Financial incentives may not be sustainable outside a research setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TOBACCO USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina, 27705-3875, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.